Valorization Team (together with DCVA)

Rob de Ree is Chair of valorization at the Dutch Cardiovascular Alliance (DCVA), co-manager along RegMed XB of FIRST, a joint early phase investment fund. Rob started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden. Rob joined Medtronic in 1996 where he worked in various sales and marketing roles, and then he moved to Crucell where he led the licensing business after which he joined BMEYE, a startup in hemodynamic monitoring where he serves as CEO until it was sold to Edwards Lifesciences.

Rob was subsequently CEO of Dezima Pharma, which was sold to Amgen in October 2015. Currently, Rob is operating partner at Biogeneration Ventures since 2016, serving on the board and in interim management positions in the fund’s portfolio companies. In addition, he is CEO of NorthSea Therapeutics and serves on the board of Mellon Medical.

• BGV - Rob de Ree

Margien Boels is an Impact Officer at the Dutch Cardiovascular Alliance (DCVA), where she’s responsible for the commercialization & valorization of DCVA consortia into solutions for patients and scalable biomed start-ups. She obtained a master’s degree in Nutrition and Health from Wageningen University and continued her academic career pursuing a Ph.D. degree in Medicine from Leiden University Medical Center in 2016 with the project “The glomerular endothelial glycocalyx in diabetic nephropathy, as part of a consortium of the Dutch Kidney Foundation. Later one, she worked as a stakeholder manager and as a Medical affairs Manager for Nutricia Nederland Medical.

• LinkedIn - Margien Boels